EDAP to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Ryan Rhodes will engage in a fireside chat and conduct one-on-one investor meetings during the event.

The presentation is scheduled for Tuesday, September 9th, 2025, from 8:30-9:00 AM ET at the Lotte New York Palace Hotel. Investors can access both the live and archived webcast through the company's investor relations website.

News Market Reaction

+1.48%

4 alerts

+1.48% News Effect

+4.7% Peak Tracked

+$856K Valuation Impact

$59M Market Cap

0.5x Rel. Volume

On the day this news was published, EDAP gained 1.48%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.7% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $856K to the company's valuation, bringing the market cap to $59M at that time.

Data tracked by StockTitan Argus on the day of publication.

AUSTIN, Texas, August 25, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 27^th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City.

Date:             Tuesday, September 9^th

Time:             8:30-9:00 AM ET

Location:       Lotte New York Palace Hotel

Webcast:      https://journey.ct.events/view/ede7e5df-b6f5-4ffb-a947-50a936dfb93b

The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One^® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com

FAQ

When is EDAP's presentation at the H.C. Wainwright Conference 2025?

EDAP will present on Tuesday, September 9th, 2025 from 8:30-9:00 AM ET at the Lotte New York Palace Hotel in New York City.

Who will represent EDAP at the H.C. Wainwright Conference 2025?

Ryan Rhodes, EDAP's Chief Executive Officer, will participate in a fireside chat and host one-on-one investor meetings.

How can investors access EDAP's H.C. Wainwright Conference presentation?

Investors can access both the live and archived webcast of the presentation through EDAP's investor relations website.

What type of meetings will EDAP conduct at the H.C. Wainwright Conference?

EDAP will participate in a fireside chat presentation and host one-on-one investor meetings during the conference.